Evidence map›Paper›PMID 41282468›Full record

ArticleMolecular therapy. Oncology2025

Newly identified oncolytic VSV-GP-specific CD8

Sarah Danklmaier, Saskia V Vijver, Lisa Pipperger, Gabriel Floriani, Lukas Perro, Vanessa Konrad, Tamara Hofer, Hubert Hackl, Krishna Das, Guido Wollmann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sarah DanklmaierInstitute of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Saskia V VijverInstitute of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Lisa PippergerInstitute of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Gabriel FlorianiInstitute of Bioinformatics, Biocenter, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Lukas PerroInstitute of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Vanessa KonradTyrolean Cancer Research Institute (TKFI), 6020 Innsbruck, Austria.
Tamara HoferInstitute of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Hubert HacklInstitute of Bioinformatics, Biocenter, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Krishna DasViraTherapeutics GmbH, 6063 Rum, Austria.
Guido WollmannInstitute of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The vesicular stomatitis virus variant VSV-GP is an oncolytic virus (OV) platform extensively studied in preclinical settings, which recently entered clinical trial testing. For oncolytic virotherapy, innate and adaptive immune system activation are considered major contributors. However, upon OV treatment, in addition to potential anti-tumor, anti-viral T cells are also raised, and comprehensively monitoring these anti-viral T cells presents a major challenge. Therefore, we aimed to identify anti-viral CD8

Indexed as

anti-viral immunityBALB/cCD8+ T cell epitopeCT26 tumor modelMHC-IMT: Regular Issueoncolytic viruspredictionVSV

Identifiers

PMID41282468
PMCPMC12634848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.